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Background/Aims: Family history (FHx) of coronary heart disease (CHD) is a 
well-known risk factor for CHD. However, the prognostic implication of FHx has 
not been established clearly in patients with acute myocardial infarction (AMI).  
Methods: In total, 11,612 patients (8,132 males [70%], age 63 ± 13 years) with first-
onset AMI between November 2005 and June 2008 in a nationwide, prospective, 
multicenter, online registry (the Korea AMI Registry) were analyzed. Clinical 
characteristics and outcomes (cardiac death and major adverse cardiac events 
[MACEs]) were assessed according to the presence of FHx.
Results: The patients with FHx were younger and included more males. Male 
patients with FHx included more current smokers and individuals with poor 
lipid profiles. In all patients, after adjustment using the Cox proportional hazard 
model, FHx was related to the risk of MACEs (hazard ratio [HR], 1.41; p = 0.009) 
and cardiac death (HR, 1.56; p = 0.080). The poor prognostic implication of FHx 
was further augmented in females and a low risk subset of patients. A significant 
interaction was only found between male and female patients for composite 
MACEs (p for interaction = 0.057), and between patients with more risk factors (≥ 
2 risk factors) and fewer risk factors for cardiac deaths (p for interaction = 0.008).
Conclusions: FHx may be an independent prognostic predictor, especially in 
female patients and patients with low-risk profile.
Keywords: Coronary disease; Myocardial infarction; Risk factors; Epidemiology
INTRODUCTION
Familial history (FHx) has long been considered a major 
risk factor for coronary heart disease (CHD). FHx was 
emphasized as a major nonmodifiable risk factor from 
the National Cholesterol Education Program Adult Treat-
ment Panel (NCEP-ATP) III guidelines [1]. Other major 
risk factors for CHD, such as old age, renal insufficiency, 
hypertension, and diabetes mellitus (DM), were reported 
as predictors of mortality in patients with CHD in pre-
vious studies [2-5]. However, the prognostic implication 
of FHx in patients with CHD has not been studied suf-
ficiently. There were three studies insisted on negative 
prognostic implication of FHx, which studies had the 
limitation of small population [6-8]. Another study in-
sisted that FHx was related to better prognosis in patients 
with f irst-onset acute myocardial infarction (AMI) [9]. 
Those studies were from about 10 years ago when revas-
cularization using drug eluting stents was not common. 
Furthermore, those studies did not consider sufficiently 
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clinical variables, such as therapeutic strategies, which 
have developed continuously in recent years.
This aim of this study was to reveal the prognostic im-
plication of FHx in the setting of secondary prevention 
and to evaluate the impact of FHx on disease presenta-
tion in patients with first-onset AMI in the current clini-
cal environment. As part of the Korea AMI Registry (KA-
MIR) study, we focused on the prognostic implication of 
FHx in a Korean population.
METHODS
Study population
KAMIR is a prospective, multicenter, online national sur-
vey designed to reflect the clinical features, and progno-
sis of AMI in the Korean population with support from 
the Korean Circulation Society. KAMIR was launched in 
2005 with a nationwide effort to collect data from patients 
with AMI admitted to 49 major cardiac centers capable 
of primary percutaneous coronary intervention (PCI) in 
Korea.
Data of 11,612 patients (8,132 males [70%], age 62.7 ± 12.6 
years) who were enrolled in KAMIR between November 
2005 and June 2008 were used in this study. Patients suf-
fering from ST-segment elevation myocardial infarction 
(STEMI) and non-ST segment elevation myocardial in-
farction (NSTEMI) were enrolled. Diagnosis with STEMI 
was decided by new or presumed new ST-segment eleva-
tion of ≥ 2 mm in more than two precordial leads or ≥ 1 
mm in more than two limb leads or new left bun-
dle-branch block on the index or subsequent 12-lead elec-
trocardiogram with positive cardiac biochemical mark er 
of necrosis (creatine kinase-MB, troponin I, or T). Pa-
tients who were diagnosed with CHD before study en-
rollment were excluded. Patients younger than 30 years 
were also excluded because of the possibility of hereditary 
disorders, congenital anomalies, or vasculitis such as Ka-
wasaki disease. FHx was defined as a first degree male 
relative with CHD under 55 years or a first degree female 
relative with CHD under 65 years. Patients with and 
without FHx are referred to as FHx+ and FHx-, respec-
tively.
Past medical history, including medication use, was re-
viewed from medical records or depended on patient-re-
ported information if no medical record was accessible. 
Nonresponses or “unknown” answers were considered as 
“no.”
Initial therapeutic strategy, including PCI, thromboly-
sis, or conservative management and medication, was de-
cided by the cardiologist, according to the American Col-
lege of Cardiology and the American Heart Association 
guidelines for the management of patients with acute 
coronary syndrome.
Study endpoints
The primary endpoint was cardiac death and the com-
posite major adverse cardiac event (MACE), including 
cardiac death, nonfatal myocardial infarction (MI), and 
revascularization (repeated PCI or coronary artery bypass 
graft after index admission) within 1 year from index 
admission. All deaths were considered as cardiac deaths 
unless a noncardiac cause of death was confirmed. 
Patients were informed to visit the outpatient clinic of 
the cardiology department after 1 month from discharge 
and then every 6 months after the PCI procedure, or 
whenever angina-like symptoms occurred.
Statistical analysis
Data are expressed as total numbers and proportion (%) 
or means ± SD. Nonparametric Mann-Whitney U tests 
were used to compare the median follow-up periods for 
FHx+ and FHx- patients. Differences in variables between 
two groups were analyzed using the chi-squared test or 
Fisher exact test for categorical variables or by the two-
tailed unpaired t test for continuous variables to compare 
baseline clinical and angiographic characteristics. The 
Cox proportional hazard regression model was used to 
analyze the prognostic implication of FHx for mortality 
or composite MACEs. In model 1, the analysis used co-
variates including age, gender, BMI, and conventional 
risk factors, including hypertension, DM, dyslipidemia, 
and current smoking. Model 2 included left ventricular 
ejection fraction (LVEF) in addition to the covariates in 
model 1 to ref lect severity of infarction and/or baseline 
cardiac function at index admission. Model 3 included 
estimated glomerular f iltration rate (eGFR), calculat-
ed from serum creatinine levels using the prediction 
equation from the Modification of Diet in Renal Disease 
Study Group [10] in addition to the covariates in model 2 
because renal dysfunction was also assessed as an inde-
pendent prognostic factor in previous studies [11,12]. All 
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statistical procedures were performed using the PASW 
software version 18.0 (IBM Co., Armonk, NY, USA).
RESULTS
Baseline characteristics and laboratory findings
The median duration of follow-up was 341 days (inter-
quartile range [IQR], 36 to 388). The median duration 
of follow-up was 359 days (IQR, 151 to 389) for FHx+ pa-
tients and 339 days (IQR, 34 to 388) in FHx- patients (p = 
0.001). FHx+ patients included more males (8,132 [81%] 
vs. 3,480 [69%]; p < 0.001) and were younger (53.9 ± 11.7 
years vs. 60.0 ± 12.2 years in males, 64.6 ± 11.8 years vs. 
70.2 ± 10.1 years in females; both p < 0.001). Dyslipid-
emia was more common among FHx+ patients before 
the index admission (13% vs. 7% in males, p < 0.001; 
14% vs. 8% in females, p = 0.003). Male patients with 
FHx included more current smokers (65% vs. 57%; p 
< 0.001). In female patients, there was no significant 
difference in laboratory findings except eGFR. How-
ever, FHx+ was related to poor lipid profiles including 
higher total cholesterol (191.6 ± 44.8 mg/dL vs. 181.3 ± 
42.4 mg/dL; p < 0.001), triglycerides (146.4 ± 125.7 mg/
dL vs. 130.7 ± 112.2 mg/dL; p = 0.002), and low density 
lipoprotein cholesterol (LDL-C) level (123.2 ± 40.6 mg/
dL vs. 115.4 ± 37.4 mg/dL; p < 0.001) in male patients 
(Table 1).
Impact of FHx on AMI presentation
There was no statistically significant difference in the 
proportion of STEMI and NSTEMI between FHx+ and 
FHx- patients. More FHx+ patients presented with Kil-
lip classification I (82% vs. 74%; p < 0.001) and higher 
LVEF (54.3% ± 11.9% vs. 51.8% ± 12.4%; p < 0.001). FHx+ 
patients were treated more aggressively with revascu-
larization compared with FHx- patients (90% vs. 86%; 
p = 0.007). There was no significant difference between 
FHx+ and FHx- patients in the presence of significant 
stenosis, the number of diseased vessel, or culprit ves-
sel lesions confirmed by coronary angiography (Table 2).
Impact of FHx on clinical outcomes
FHx+ patients had a lower incidence of cardiac death 
(3.0% vs. 6.2%, p < 0.001) but there was no significant 
difference in the incidence of composite MACEs (10.3% 
vs. 11.5%, p = 0.132). Because significant differences 
were found in baseline characteristics and event rates 
of cardiac deaths (4.4% vs. 9.8%, p < 0.001) and com-
posite MACEs (15% vs. 10%, p < 0.001) between male 
and female patients (Table 3), prognostic analyses were 
performed separately for males and females.
In multivariate analysis, the adjusted hazard ratio (HR) 
of FHx was 1.56 (95% confidence interval [CI], 0.95 to 2.55; 
p = 0.080) for cardiac death and 1.41 (95% CI, 1.09 to 1.82; 
p = 0.009) for composite MACEs in all patients (model 3). 
The prognostic implication of FHx were significant in 
female patients. A HR of FHx was 2.02 (95% CI, 0.98 to 
4.17; p = 0.056) for cardiac death and 2.07 (95% CI, 1.32 to 
3.24; p = 0.002) for composite MACEs in female patients. 
However, in male patients, no significant difference was 
found between FHx+ and FHx- patients. A HR of FHx+ 
was 1.29 (95% CI, 0.65 to 2.53; p = 0.467) for cardiac deaths 
and 1.22 (95% CI, 0.89 to 1.65; p = 0.215) for com posite 
MACEs in male patients (Table 4).
Further analyses were performed with dichotomous 
subgrouping according to ST-elevation, age, LVEF, MI lo-
cation, GRACE score, and number of risk factors (includ-
ing hypertension, DM, dyslipidemia [previous diagnosis, 
LDL-C ≥ 160 mg/dL, high density lipoprotein cholesterol, 
HDL-C < 40 mg/dL, and triglycerides ≥ 200 mg/dL]) (Fig. 
1). The prognostic implication of FHx was statistically 
significant only in older patients (≥ 60 years in males, ≥ 
70 years in females) and patients with higher LVEF (≥ 
50%), NSTEMI, or fewer risk factors. However, no signifi-
cant interaction was found between each paired group 
except between male and female patients for composite 
MACEs (p = 0.057) and high (≥ 2 risk factors) and lower 
risk groups for cardiac deaths (p value for interaction = 
0.008) (Fig. 1). In patients with fewer risk fa ctors, a HR of 
FHx was 2.65 (95% CI, 1.394 to 5.024; p = 0.003) for cardiac 
deaths and 1.51 (95% CI, 1.019 to 2.245; p = 0.040) for com-
posite MACEs.
DISCUSSION 
In this study, we intended to assess the significance 
of FHx as an independent predictor in the setting of 
secondary prevention. The FHx+ group was younger 
and included more male patients. Patients with FHx 
included more current smokers and had poor lipid 
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profiles, especially the males. FHx was related inde 
pendently to poor clinical outcomes by survival analy-
sis using a multivariate regression model.
Familial clustering of CHD has been demonstrated 
and FHx is considered a risk factor for CHD. In 1966, 
Slack and Evans [13] studied the relatives of patients with 
CHD and showed higher mortality from CHD. Since the 
1980s, a few prospective studies have indicated that FHx 
is an independent risk factor, even after adjusting for 
other risk factors [14-17] and the NCEP-ATP III guide-
lines [1] included FHx as a major risk factor for CHD. 
The Framingham Study also revealed that FHx was asso-
ciated with a risk of cardiovascular outcome; however, 
the Framingham risk score (FRS), a prediction model of 
CHD, did not include FHx in the equation [18]. Recent 
studies insisted that FRS may underestimate the risk of 
CHD in low-risk individuals with FHx [19,20]. In the 
Multi-Ethnic Study of Atherosclerosis (MESA) study, 
there was association between the presence of coronary 
artery calcium score and FHx independently from FRS 
Table 1. Demographic and biochemical characteristics at index hospitalization
Characteristic
All
(n = 11,612)
Males (n = 8,132) Females (n = 3,480)
FHx+
(n = 588)
FHx-
(n = 7,544)
p value
FHx+
(n = 139)
FHx-
(n = 3,341)
p value
Age, yr   62.7 ± 12.6  53.9 ± 11.7   60.0 ± 12.2 < 0.001  64.6 ± 11.8  70.2 ± 10.1  < 0.001
Height, cm     163.5 ± 8.8    168.4 ± 5.7   167.4 ± 6.1 < 0.001  156.6 ± 5.9  153.5 ± 6.1  < 0.001
Weight, kg   64.1 ± 11.4  70.6 ± 10.1    67.4 ± 10.4 < 0.001  59.7 ± 10.2  55.4 ± 9.0  < 0.001
BMI, kg/m2 23.9 ± 3.2     24.9 ± 2.9    24.0 ± 3.1 < 0.001  24.4 ± 3.7  23.5 ± 3.4    0.003
Past medical history
Hypertension  5,340 (46) 239 (41) 3,040 (40)    0.868 89 (64) 1,972 (59)    0.239
DM  5,127 (44) 242 (41) 3,225 (43)    0.452 69 (50) 1,591 (48)    0.640
Dyslipidemia  904 (8)   77 (13)  556 (7) < 0.001 20 (14)  251 (8)    0.003
CVA   752 (7)  21 (4)  452 (6)    0.016  5 (4)  274 (8)    0.050
PAD   98 (1)    4 (1)   63 (1)    0.689  0 (0)   31 (1)    0.254
CKD  224 (2)    2 (0)  141 (2)    0.007  3 (2)   78 (2)    0.893
Smokersa 5,070 (44)  381 (65) 4,275 (57) < 0.001  14 (10)  400 (12)    0.498
Laboratory findings
Glucose, mg/dL  170.0 ± 82.6  154.7 ± 68.5  166.0 ± 78.2 < 0.001  175.5 ± 110.0  181.6 ± 91.6    0.442
eGFR, mL/min/1.73 m2   78.2 ± 36.8  87.2 ± 53.7     80.7 ± 37.6 < 0.001  78.1 ± 31.0  71.6 ± 31.2    0.009
Peak CK, unit/L    1,431 ± 1,982    1,706 ± 2,082   1,558 ± 2,145    0.139  1,142 ± 1,604  1,105 ± 1,494    0.800
Peak CK-MB, unit/L   126 ± 182   137 ± 159      134 ± 194    0.748  115 ± 216  106 ± 152   0.521
Peak TnI, mg/dL   45.7 ± 83.0   55.4 ± 90.2    48.6 ± 87.7    0.106  39.9 ± 71.8  38.0 ± 70.3   0.783
TC, mg/dL 184.3 ± 44.5 191.6 ± 44.8   181.3 ± 42.4 < 0.001  190.6 ± 49.8  190.0 ± 48.1   0.834
Triglyceride, mg/dL   128.0 ± 106.0  146.4 ± 125.7   130.7 ± 112.2    0.002  126.8 ± 83.3  118.7 ± 87.3   0.301
HDL-C, mg/dL  44.6 ± 12.0   43.2 ± 10.9    43.8 ± 11.6    0.164  47.5 ± 12.1  46.4 ± 12.6   0.356
LDL-C, mg/dL 117.8 ± 39.1  123.2 ± 40.6   115.4 ± 37.4 < 0.001  121.7 ± 38.0  122.1 ± 42.3    0.913
hsCRP, mg/dL   13.6 ± 53.8   13.9 ± 58.2    12.5 ± 49.8    0.572  11.1 ± 39.4  16.1 ± 61.6    0.402
NT-proBNP, pg/mL   2,663 ± 6,050  1,146 ± 3,787  2,044 ± 5,299 < 0.001  3,375 ± 7,095  4,259 ± 7,407    0.274
Values are presented as mean ± SD or number (%).
FHx, family history; BMI, body mass index; DM, diabetes mellitus; CVA, cerebrovascular disease; PAD, peripheral vascular 
disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; CK, creatine kinase; TnI, troponin-I; TC, 
total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hsCRP, high-
sensitivity C-reactive protein; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
aSmokers are defined as people who smoked at least 100 cigarettes in a lifetime and currently smoke every day or some days. 
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Table 2. Presentation of acute myocardial infarction, therapeutic strategies, and angiographic characteristics
Characteristic
All
(n = 11,612)
Males (n = 8,132) Females (n = 3,480)
FHx+
(n = 588)
FHx-
(n = 7,544)
p value
FHx+
(n = 139)
FHx-
(n = 3,341)
p value
STEMI/NSTEMI
  7,125 (61)/
4,303 (37)
  382 (65)/
203 (35)
 4,822 (65)/
2,597 (35)
   0.882
       76 (55)/
        63 (45)
     1,845 (56)/
   1,440 (44)
0.729
Killip class I     9,601 (83)  475 (83) 5,492 (77)    0.001 101 (77)    2,100 (66) 0.010
LVEF, % 51.9 ± 12.4  54.3 ± 11.7 51.9 ± 12.0 < 0.001 54.4 ± 12.7       51.5 ± 13.1 0.013
Revascularization   10,007 (86)   531 (90)  6,675 (89)    0.180 120 (86)     2,681 (80) 0.076
PCI 9,618 (83)  510 (87) 6,410 (85)    0.247 116 (84)       2,582 (77) 0.088
CABG  323 (3)  14 (2)  213 (3)    0.530 4 (3)          92 (3) 0.930
Thrombolysis  813 (7)  50 (9)  607 (8)    0.695  5 (4)         151 (5) 0.607
Angiographic findings
Significant stenosis   10,226 (95)  536 (95) 6,805 (96)    0.320 123 (94)     2,762 (93) 0.684
Extent of disease    0.686 0.955
1-VD 4,371 (43)   251 (47) 3,043 (45)  45 (37)     1,032 (38)
2-VD 3,072 (31)   157 (30) 2,012 (30) 40 (33) 863 (32)
3-VD or LM 2,636 (26)  124 (23) 1,653 (25)  36 (30)  823 (30)
Culprit vessel    0.584 0.683
LAD 4,885 (48)  266 (50)  3,255 (49) 54 (44)      1,310 (48)
LCX 1,619 (16)   90 (17) 1,070 (16) 24 (20) 435 (16)
RCA 3,386 (34)  164 (31) 2,257 (34) 43 (35) 922 (34)
LM 203 (2)   9 (2)  136 (2) 2 (2) 56 (2)
Values are presented as number (%) or mean ± SD.
FHx, family history; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST segment elevation myocardial 
infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass 
graft; VD, vessel disease; LM, left main trunk; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right 
coronary artery.
Table 3. Impact of family history on clinical outcomes: univariate analyses
FHx+ FHx- Hazard ratio
(95% CI)
p value
No. of patients Events No. of patients Events
Cardiac death
Overall 727 22 (3) 10,885  679 (6) 0.46 (0.30–0.71) < 0.001
Male 588  13 (2)   7,544  348 (5) 0.46 (0.27–0.81)    0.006
Female 139   9 (7)   3,341     331 (10) 0.62 (0.32–1.19)   0.150
Composite MACEs
Overall 727   75 (10) 10,885 1,250 (11) 0.84 (0.66–1.06)   0.132
Male 588  53 (9)   7,544     759 (10) 0.85 (0.64–1.12)   0.237
Female 139   22 (16)   3,341    491 (15) 0.97 (0.64–1.49)    0.904
Values are presented as number (%). Hazard ratio of family history was determined by Cox proportional hazard regression 
analysis without covariate adjustment. 
FHx, family history; CI, confidence interval; MACEs, major adverse cardiac events. 
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or other traditional risk factors and it was revealed most 
significantly in Asian ethnicity [21]. These studies evalu-
ated FHx as a risk factor for CHD events or clinical out-
comes among the general population who did not suffer 
from CHD.
FHx, as an aspect of secondary prevention, had very 
limited evidence in support of the independent implica-
tion for clinical outcomes. Four studies have evaluated 
the prognostic implication of FHx as an independent risk 
factor in the patients with CHD. Tadros et al. [6] found 
that FH was an independent predictor of 30-day MACEs 
(odds ratio [OR], 3.56; 95% CI, 1.25 to 6.57; p = 0.01; n = 383). 
In other studies of post-PCI patients, FHx was related to 
adverse events during hospitalization (OR, 2.75; 95% CI, 
0.93 to 8.11; n = 197) and after discharge (OR, 1.41; 95% CI, 
0.98 to 2.04) [7], and to overall death and cardiovascular 
events after a 1-year follow-up (OR, 4.6; 95% CI, 1.7 to 12.8; 
p < 0.005; n = 135) [8]. However, these studies were per-
formed in small populations. In an Israeli study with 
2,960 first-onset AMI patients [9], FHx was independent-
ly related to lower 1-year mortality (HR, 0.58; 95% CI, 0.42 
to 0.80; p < 0.001) contrary to common expectations. The 
investigators in the study suggested that the association 
between FHx and favorable outcomes might be mostly 
due to the younger age of the patients with FHx com-
pared with those without FHx. Furthermore, the study 
could be inf luenced by selection bias because only pa-
tients who were admitted to intensive care units were in-
cluded. The age difference between the patients with and 
without FHx was greater (53 years vs. 64 years) than in our 
study (56 years vs. 63 years). Additionally, the analysis was 
only of mortality, not composite MACEs, as the clinical 
outcome.
We found that FHx was independently related to poor 
prognosis. FHx was related to poor clinical outcomes af-
ter adjustment, but not significantly so, and to cardiac 
death in all patients. Because cardiac death was infre-
quent (701, 6.0%) especially in the FHx+ group (22, 3.0%), 
the statistical significance may be underpowered com-
pared with that of composite MACEs (1,325, 11.4% in all 
patients; 75, 10.3% in the FHx+ group).
Our study showed that FHx was a significant prognos-
tic indicator, which was further augmented in female pa-
tients. To reveal the difference in the impact of FHx be-
tween male and female patients, we compared the 
significance of the impact of FHx between both patients 
in subgroups with or without each risk factor (hyperten-
sion, diabetes, dyslipidemia, smoking, and any risk fac-
tor). However, there was no statistically significant differ-
ence in the subgroup analyses. The disparities of impact 
of FHx from each subgroups may be caused by less influ-
ence of FHx on outcomes than other major risk factors. 
Table 4. Impact of family history on clinical outcomes: multivariate Cox proportional hazard analysis
Overall Males Females
Hazard ratio
(95% CI)
p value
Hazard ratio
(95% CI)
p value
Hazard ratio
(95% CI)
p value
Cardiac death
Age-gender-adjusted 0.72 (0.47–1.11) 0.134  0.69 (0.40–1.20) 0.188  0.78 (0.40–1.52) 0.471
Model 1  1.04 (0.67–1.61)  0.867 0.97 (0.54–1.75)  0.930   1.14 (0.58–2.22)  0.706
Model 2   1.45 (0.89–2.38) 0.137  1.23 (0.63–2.43) 0.544  1.89 (0.92–3.89)  0.085
Model 3  1.56 (0.95–2.55)   0.080  1.29 (0.65–2.53) 0.467  2.02 (0.98–4.17)  0.056
Composite MACEs
Age-gender-adjusted 1.05 (0.83–1.33)  0.693  1.01 (0.77–1.34)  0.926  1.14 (0.74–1.76) 0.543
Model 1 1.24 (0.94–1.57)  0.085   1.15 (0.86–1.53) 0.341   1.45 (0.94–2.24)  0.090
Model 2  1.37 (1.06–1.77)  0.015   1.20 (0.89–1.63) 0.255  1.94 (1.24–3.04)  0.004
Model 3  1.41 (1.09–1.82)   0.009   1.22 (0.89–1.65) 0.215 2.07 (1.32–3.24)  0.002
In model 1, covariates were age, gender, body mass index, hypertension, diabetes mellitus, dyslipidemia, current smoking. 
Model 2 included left ventricle ejection fraction in addition to the covariates in model 1. Model 3 included estimated 
glomerular filtration rate in addition to the covariates in model 2. 
CI, confidence interval; MACEs, major adverse cardiac events.
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A.     Cardiac deaths
Subgroup No. of patients
FHx+ group FHx- group
Hazard ratio (95% CI)
p value
for interaction
No. of 
patients
Events,
no. (%)
No. of 
patients
Events,
no. (%)
Overall 11,612 727 22 (3) 10,885    679 (6)
Sex 0.248
Male 8,132 588 13 (2) 7,544    348 (5)
Female 3,480 139  9 (7) 3,341     331 (10)
ST-elevation 0.337
STEMI 7,125 458  12 (3) 6,667    491 (7)
NSTEMI 6,703 266 10 (4) 4,037     183 (5)
Age 0.391
M ≥ 60/F ≥ 70 5,982 217 15 (3) 5,765    528 (9)
M < 60/F < 70 5,630 510  7 (1) 5,120     151 (3)
LVEF 0.503
≥ 50% 6,070 454   7 (2) 5,616    98 (2)
< 50% 4,185 208  11 (5) 3,977    277 (7)
MI location 0.625
Anterior MI 6,121 386   9 (2) 5,735    380 (7)
Nonanterior MI 488 306   8 (3) 4,538    233 (5)
GRACE score 0.165
≥ 141 5,954 249 18 (7) 5,705    573 (10)
≤ 140 4,660 438  3 (1) 4,222    39 (1)
Rick factors 0.008
2 or more 7,190 495  10 (2) 6,695    402 (6)
0 or 1 4,422 232  12 (5) 4,190    277 (7)
0.4                1.0                                    8.0
Favorable UnfavorableB.     Composite MACEs
Subgroup No. of patients
FHx+ group FHx- group
Hazard ratio (95% CI)
p value
for interaction
No. of 
patients
Events,
no. (%)
No. of 
patients
Events,
no. (%)
Overall 11,612 727   75 (10) 10,885 1250 (11)
Sex 0.055
Male 8,132 588   53 (9) 7,544  759 (10)
Female 3,480 139   22 (16) 3,341 491 (15)
ST-elevation 0.396
STEMI 7,125 458   46 (10) 6,667 857 (13)
NSTEMI 6,703 266   29 (11) 4,037  385 (10)
Age 0.599
M ≥ 60/F ≥ 70 5,982 217   32 (15) 5,765 803 (14)
M < 60/F < 70 5,630 510  48 (8) 5,120 447 (9)
LVEF 0.524
≥ 50% 6,070 454  40 (9) 5,616 430 (8)
< 50% 4,185 208   28 (14) 3,977  477 (12)
MI location 0.505
Anterior MI 6,121 386   38 (10) 5,735 665 (12)
Nonanterior  MI 4.844 306   32 (11) 4,538 507 (11)
GRACE score 0.285
≥ 141 5,954 249   41 (17) 5,705 873 (15)
≤ 140 4,660 438  32 (7) 4,222 287 (7)
Rick factors 0.172
2 or more 7,190 495   48 (10) 6,695 786 (12)
0 or 1 4,422 232   27 (12) 4,190 464 (11)
0.4                1.0                                    8.0
Favorable Unfavorable
Figure 1. Adjusted hazard ratio of family history (FHx) for clinical outcome, according to prespecified subgroup. Hazard ratio 
was calculated using Cox proportional hazard regression model adjusted with age, sex, body mass index, hypertension, diabetes 
mellitus, smoking, left ventricular ejection fraction, and estimated glomerular filtration rate (model 3). GRACE score is an index 
to predict in-hospital or 6 months mortality in the patients with acute coronary syndrome. Risk factors included hypertension, 
diabetes mellitus, dyslipidemia (previous diagnosis, low density lipoprotein cholesterol ≥160 mg/dL, high density lipoprotein 
cholesterol <40 mg/dL, triglyceride ≥200 mg/dL) and current smoking. (A) Cardiac deaths. (B) Composite MACEs. 
CI, confidence interval; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST segment elevation myocardial 
infarction; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MACEs, major adverse cardiac events.
A
B
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And FHx itself may be related to other risk factors as well. 
Which risk factors and how much each risk factor affects 
the outcomes may also differ between male and female 
patients. Further subgroup analyses of each variable risk 
factors separately would be needed to assess the interac-
tion between FHx and other risk factors. Despite these 
possibilities, FHx was independently associated with a 
poor outcome, and this may have significance for second-
ary prevention strategies in patients with first-onset AMI.
The relationship between female gender and FHx has 
been reported. An epidemiological study of the impact of 
FHx on the incidence of CHD revealed that maternal his-
tory may be more important in terms of increasing the 
risk [22]. The reason for gender differences in CHD re-
mains unclear, but several mechanisms have been pro-
posed, such as hormonal effects on lipid metabolism, in-
sulin resistance, and thrombogenic factors. Poor lipid 
prof iles, including elevated levels of LDL-C and tri-
glycerides or low levels of HDL-C, are known to be relat-
ed to CHD and other vascular diseases. Previous stud-
ies revealed that poor lipid profiles may have greater 
predictive potential for CHD incidence and mortality, 
especially in female patients [23-26]. However, another 
study indicated that FHx (OR, 5.11 vs. 3.14; p < 0.05) and 
hypercholesterolemia (OR, 3.77 vs. 2.19; p < 0.05) were as-
sociated with a higher risk of CHD in male patients [27]. 
In our study, a significant difference in lipid profiles 
between the FHx+ and FHx- group was only seen in 
male patients. However, true differences in lipid profiles 
caused by FHx may have been hidden in the female pa-
tients because the FHx- group included older patients, 
and total cholesterol and triglyceride levels tend to di-
minish with increasing age [28].
In our study, the prognostic implication of FHx was 
also further augmented in patients with fewer risk fac-
tors, especially for cardiac deaths. Some previous studies 
that emphasized a correlation between FHx and CHD 
suggested that FHx may be more important in low-risk 
patients [29-31]. A recent study of the MESA cohort [21] 
found that FHx was related to higher plaque burden, con-
sidered a risk for CHD, and the correlation was indepen-
dent of other risk factors or FRS. Otherwise, there was no 
significant difference in the prognostic implication of 
FHx between the higher and lower GRACE score groups. 
The importance of FHx in evaluating the risk of CHD 
might have been underestimated, especially in patients at 
lower risk, as classified by traditional risk stratification 
systems, such as the number of conventional risk factors 
and FRS. Further studies will reveal the prognostic im-
plication of FHx in various risk stratification systems.
Study limitations
First, although we used a large population, this was a 
retrospectively analysis of a multicenter prospective 
registry, and it was not randomized or controlled. 
The difference in age and gender was considerable, 
those factors could be significantly related to progno-
sis. Though we attempted to minimize the effects of 
confounders by adjustment, interference might not 
have been totally excluded, and some other potential 
confounders, such as socioeconomic factors, may have 
been present.
The 6.3% rate of FHx was lower compared with other 
studies in Western populations and other Asian ethnici-
ties. Indeed, 15.6% of Japanese patients undergoing coro-
nary intervention had FHx [32]. It is possible that the low 
incidence of FHx compared to CHD events is a result of 
the rapid increase in the incidence of CHD in Korea. 
However, the validity of FHx of CHD in our study was 
likely not high because confirmation of FHx depended 
mainly on patient self-reporting. Thus, the lower report-
ed rate of FHx might have been related to ignorance of 
the implication of FHx on CHD of patients and/or physi-
cians.
It is not certain whether patients enrolled in KAMIR 
are representative of all MI patients in Korea because KA-
MIR includes only patients admitted to major cardiac 
centers capable of primary PCI. However, the exclusion of 
PCI-incapable medical centers might not have affected 
the results of our study because in Korea it is possible to 
be admitted or transferred to a PCI capable medical cen-
ter within 2 hours if primary PCI is required.
KEY MESSAGE 
1. Family history may not influence on the clinical 
presentation in patients with first-onset myo-
cardial infarction.
2. However, family history has a significant impact 
on clinical outcome, especially in the subsets of 
female or lower risk patients.
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